Completed PHASE2 INTERVENTIONAL 4-arm NCT01386242

Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer

Phase II/III Study of Recombinant Anti-tumor and Anti-Virus Protein for Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Second-Line and More Than Second-line Treatment

Sponsor: Beijing Genova Biotech Company, Ltd.

Conditions Metastatic Colorectal Cancer

Interventions Recombinant anti-tumor and anti-virus protein for injection Saline Injection

Updated 5 times since 2017 Last updated: Jan 4, 2016 Started: May 31, 2011 Primary completion: May 31, 2013 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01386242, this PHASE2 trial focuses on Metastatic Colorectal Cancer and remains completed. Sponsored by Beijing Genova Biotech Company, Ltd., it has been updated 5 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Genova Biotech Company, Ltd.
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Data source: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China